PubRank

E Maraskovsky

Author PubWeight™ 64.71‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice. J Exp Med 1994 8.97
2 A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997 8.59
3 Distinct dendritic cell subsets differentially regulate the class of immune response in vivo. Proc Natl Acad Sci U S A 1999 5.66
4 Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. Blood 2000 5.06
5 Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med 1999 4.92
6 Fas transduces activation signals in normal human T lymphocytes. J Exp Med 1993 3.04
7 Developmental pathways of dendritic cells in vivo: distinct function, phenotype, and localization of dendritic cell subsets in FLT3 ligand-treated mice. J Immunol 1997 2.89
8 Interleukin (IL)-4 is a major regulatory cytokine governing bioactive IL-12 production by mouse and human dendritic cells. J Exp Med 2000 2.09
9 cMpl ligand is a humoral regulator of megakaryocytopoiesis. Nature 1994 1.85
10 Mouse thymus dendritic cells: kinetics of development and changes in surface markers during maturation. Eur J Immunol 1995 1.71
11 Modulating the immune response with dendritic cells and their growth factors. Trends Immunol 2001 1.66
12 Polyethylene glycol-modified GM-CSF expands CD11b(high)CD11c(high) but notCD11b(low)CD11c(high) murine dendritic cells in vivo: a comparative analysis with Flt3 ligand. J Immunol 2000 1.58
13 Dendritic cell development in culture from thymic precursor cells in the absence of granulocyte/macrophage colony-stimulating factor. J Exp Med 1996 1.36
14 Flt3 ligand induces tumor regression and antitumor immune responses in vivo. Nat Med 1997 1.35
15 Herpesvirus saimiri open reading frame 14, a protein encoded by T lymphotropic herpesvirus, binds to MHC class II molecules and stimulates T cell proliferation. J Immunol 1996 1.25
16 Molecular characterization of a family of ligands for eph-related tyrosine kinase receptors. EMBO J 1994 1.24
17 Prevention of peripheral tolerance by a dendritic cell growth factor: flt3 ligand as an adjuvant. J Exp Med 1998 1.20
18 FLT3 ligand induces the generation of functionally active dendritic cells in mice. Cell Immunol 1997 1.12
19 Heterogeneity in lymphokine profiles of CD4+ and CD8+ T cells and clones activated in vivo and in vitro. Immunol Rev 1991 1.09
20 Ligands for the receptor tyrosine kinases hek and elk: isolation of cDNAs encoding a family of proteins. Oncogene 1995 1.07
21 Cancer testis antigens expression in mesothelioma: role of DNA methylation and bioimmunotherapeutic implications. Br J Cancer 2002 0.97
22 Isolation of LERK-5: a ligand of the eph-related receptor tyrosine kinases. Mol Immunol 1995 0.93
23 Exogenous peptides presented by transporter associated with antigen processing (TAP)-deficient and TAP-competent cells: intracellular loading and kinetics of presentation. J Immunol 2001 0.92
24 The use of dendritic cells in cancer therapy. Lancet Oncol 2001 0.87
25 Immune responses to ISCOM formulations in animal and primate models. Vaccine 2001 0.86
26 Recombinant NY-ESO-1 cancer antigen: production and purification under cGMP conditions. Prep Biochem Biotechnol 2005 0.83
27 Quantitative analysis of lymphokine expression in vivo and in vitro. Immunol Cell Biol 1992 0.80
28 Flt3 ligand lessens the growth of tumors obtained after colon cancer cell injection in rats but does not restore tumor-suppressed dendritic cell function. Int J Cancer 2000 0.79
29 Developmental options. Science 1998 0.75
30 Ex vivo restimulation of human PBMC expands a CD3+CD4-CD8- γδ+ T cell population that can confound the evaluation of CD4 and CD8 T cell responses to vaccination. Clin Dev Immunol 2013 0.75